Respiratory

PUBLISHER: The Business Research Company | PRODUCT CODE: 1415773

PUBLISHER: The Business Research Company | PRODUCT CODE: 1415773

Pulmonary Embolism Global Market Report 2024

Published: Pre-Order

PAGES: 175 Pages

DELIVERY TIME: 2-10 business days

ADD TO COMPARE

SELECT AN OPTION

Description

“Pulmonary Embolism Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary embolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary embolism? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pulmonary embolism market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Treatment: Medications; Mechanical Devices; Other Treatments
2) By Diagnosis: Chest X-Ray; Electrocardiogram (ECG); Magnetic Resonance Imaging (MRI); Computed Tomography Scan; Pulmonary Angiography; Venography; Venous Ultrasound; D-Dimer Test; Other Diagnosis
3) By Symptoms: Shortness Of Breath; Chest Pain; Cough; Irregular Heartbeat; Dizziness; Fever; Cyanosis; Other Symptoms
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck And Co.Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

A pulmonary embolism is a condition characterized by the blockage of the pulmonary artery, which carries blood from the heart to the lungs. This blockage typically results from a blood clot that has traveled from another part of the body, most commonly the legs. Symptoms of a pulmonary embolism can vary, ranging from sudden shortness of breath to chest pain, coughing up blood or bloody mucus, and other signs, with the severity depending on the size and location of the clot.

The primary types of treatment for pulmonary embolism encompass medications, mechanical devices, surgery, and other therapeutic interventions. Medications are substances used for medical purposes to treat, manage, prevent, or alleviate various medical conditions and illnesses. Diagnosis of a pulmonary embolism involves various methods, including chest X-rays, electrocardiograms (ECGs), magnetic resonance imaging (MRI), computed tomography scans, pulmonary angiography, venography, venous ultrasound, D-Dimer tests, and others. Symptoms may include shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and more. Medications for treating pulmonary embolism are primarily distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other relevant channels. Healthcare providers in hospitals, specialty clinics, homecare settings, and other medical facilities typically manage the treatment of pulmonary embolism.

The pulmonary embolism market research report is one of a series of new reports from The Business Research Company that provides pulmonary embolism market statistics, including pulmonary embolism industry global market size, regional shares, competitors with a pulmonary embolism market share, detailed pulmonary embolism market segments, market trends and opportunities and any further data you may need to thrive in the pulmonary embolism industry. This pulmonary embolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pulmonary embolism market size has grown rapidly in recent years. It will grow from $1.81 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to anticoagulant therapies, research and clinical trials, pulmonary embolism awareness, vte prophylaxis.

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to targeted therapies, telemedicine and remote monitoring, health equity initiatives, global health initiatives. Major trends in the forecast period include artificial intelligence in diagnosis, novel anticoagulants, pulmonary embolism response teams, patient-centered care.

The burgeoning prevalence of blood clots is anticipated to be a driving force behind the growth of the pulmonary embolism market in the foreseeable future. Blood clots, medically referred to as thrombi, manifest as gel-like or semi-solid masses within blood vessels. The presence of blood clots escalates the risk of pulmonary embolism by impeding the natural flow of blood to the lungs, causing a blockage. These clots are typically observed in the deep veins of the legs, significantly increasing the likelihood of pulmonary embolism. As an illustration, a Gavi, the Vaccine Alliance article from April 2022 reported a thirty-three-fold surge in the potential occurrence of life-threatening lung clots and a five-fold increase in deep vein thrombosis risk within thirty days after COVID-19 exposure. Consequently, the escalating prevalence of blood clots is a key driver for the growth of the pulmonary embolism market.

The escalating incidence of cancer is expected to act as a catalyst for the expansion of the pulmonary embolism market. Cancer, a complex group of diseases characterized by the uncontrolled and abnormal proliferation of cells in the body, heightens the susceptibility of cancer patients to blood clots, including pulmonary embolism. This heightened risk underscores the growing demand for specialized drugs, diagnostics, and treatment solutions. As an instance, the National Library of Medicine's report in May 2021 projects a global cancer burden of 28.4 million cases in 2040, representing a substantial 47% surge from the figures in 2020, along with a corresponding increase in fatalities. This underscores the pivotal role played by the increasing prevalence of cancer in driving the expansion of the pulmonary embolism market.

The growth of the pulmonary embolism market is impeded by delayed diagnoses during the forecast period. A delay in diagnosing pulmonary embolism (PE) presents a formidable challenge for patients, increasing the risk of mortality and complications, reducing their quality of life, escalating healthcare costs, decreasing treatment demand, and placing a heavier burden on healthcare providers. For example, data from 2022, as per the National Library of Medicine, a biomedical library, indicates that untreated pulmonary embolism patients had a 30% mortality rate, in contrast to 8% among those diagnosed and treated promptly. Consequently, the hindered growth of the pulmonary embolism market can be attributed to delayed diagnoses.

Prominent companies operating in the pulmonary embolism market are dedicated to introducing cutting-edge products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to maintain a competitive edge. As of June 2023, Inari Medical Inc., a US-based medical device company, has launched the Triever16 Curve catheter and the RevCore thrombectomy catheter. The innovative Triever16 Curve catheter is specially designed for peripheral thrombectomy and pulmonary embolism procedures. Its high trackability and pre-shaped curve facilitate focused aspiration. Moreover, the catheter's unique design offers easy access to larger and more powerful 20F or 24F catheters. On the other hand, the RevCore thrombectomy catheter has been developed for the treatment of venous in-stent thrombosis. This mechanical thrombectomy device utilizes a nitinol basket for capturing and removing blood clots, enhancing the safety and efficacy of pulmonary embolism procedures.

In September 2021, Boston Scientific Corporation, a US-based medical manufacturing company, completed its acquisition of Devoro Medical Inc. for $336 million. This strategic acquisition has enriched Boston Scientific's portfolio by incorporating Devoro Medical's Wolf thrombectomy platform, designed for the removal of blood clots from peripheral blood vessels. The acquisition has further fortified Boston Scientific's position in the competitive market for vascular intervention devices. Devoro Medical Inc., a US-based medical device company specializing in innovative technologies for blood clot removal, significantly contributed to this endeavor.

Major players in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the pulmonary embolism market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pulmonary embolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The pulmonary embolism market consists of revenues earned by entities by providing services such as medical management, thrombolytic therapy, monitoring and oxygen therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulmonary embolism market also includes sales of diagnostic imaging equipment, oxygen delivery devices, interventional devices, medical alert systems and pulse oximeters. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12372

1. Executive Summary

2. Pulmonary Embolism Market Characteristics

3. Pulmonary Embolism Market Trends And Strategies

4. Pulmonary Embolism Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Pulmonary Embolism Market Size and Growth

5.1. Global Pulmonary Embolism Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Pulmonary Embolism Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Pulmonary Embolism Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pulmonary Embolism Market Segmentation

6.1. Global Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Medications
Mechanical Devices
Surgery
Other Treatments
6.2. Global Pulmonary Embolism Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Chest X-Ray
Eectrocardiogram (ECG)
Magnetic Resonance Imaging (MRI)
Computed Tomography Scan
Pulmonary Angiography
Venography
Venous Ultrasound
D-Dimer Test
Other Diagnosis
6.3. Global Pulmonary Embolism Market, Segmentation By Symptoms, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Shortness Of Breath
Chest Pain
Cough
Irregular Heartbeat
Dizziness
Fever
Cyanosis
Other Symptoms
6.4. Global Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.5. Global Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-Users

7. Pulmonary Embolism Market Regional And Country Analysis

7.1. Global Pulmonary Embolism Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Pulmonary Embolism Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pulmonary Embolism Market

8.1. Asia-Pacific Pulmonary Embolism Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pulmonary Embolism Market

9.1. China Pulmonary Embolism Market Overview
9.2. China Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pulmonary Embolism Market

10.1. India Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pulmonary Embolism Market

11.1. Japan Pulmonary Embolism Market Overview
11.2. Japan Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pulmonary Embolism Market

12.1. Australia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pulmonary Embolism Market

13.1. Indonesia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pulmonary Embolism Market

14.1. South Korea Pulmonary Embolism Market Overview
14.2. South Korea Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pulmonary Embolism Market

15.1. Western Europe Pulmonary Embolism Market Overview
15.2. Western Europe Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pulmonary Embolism Market

16.1. UK Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pulmonary Embolism Market

17.1. Germany Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pulmonary Embolism Market

18.1. France Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pulmonary Embolism Market

19.1. Italy Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pulmonary Embolism Market

20.1. Spain Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pulmonary Embolism Market

21.1. Eastern Europe Pulmonary Embolism Market Overview
21.2. Eastern Europe Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pulmonary Embolism Market

22.1. Russia Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pulmonary Embolism Market

23.1. North America Pulmonary Embolism Market Overview
23.2. North America Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pulmonary Embolism Market

24.1. USA Pulmonary Embolism Market Overview
24.2. USA Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pulmonary Embolism Market

25.1. Canada Pulmonary Embolism Market Overview
25.2. Canada Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pulmonary Embolism Market

26.1. South America Pulmonary Embolism Market Overview
26.2. South America Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pulmonary Embolism Market

27.1. Brazil Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pulmonary Embolism Market

28.1. Middle East Pulmonary Embolism Market Overview
28.2. Middle East Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pulmonary Embolism Market

29.1. Africa Pulmonary Embolism Market Overview
29.2. Africa Pulmonary Embolism Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Pulmonary Embolism Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Pulmonary Embolism Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pulmonary Embolism Market Competitive Landscape And Company Profiles

30.1. Pulmonary Embolism Market Competitive Landscape
30.2. Pulmonary Embolism Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Johnson and Johnson Private Limited
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. F. Hoffmann-La Roche Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Merck And Co.Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Pulmonary Embolism Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Sanofi S.A.
31.3. Bristol Myers Squibb Company
31.4. GSK plc
31.5. Abbott Laboratories
31.6. AstraZeneca plc
31.7. Medtronic plc
31.8. Eli Lilly and Company
31.9. Gilead Sciences Inc.
31.10. Baxter International Inc.
31.11. Teva Pharmaceutical Industries Ltd.
31.12. Regeneron Pharmaceuticals Inc.
31.13. Mylan N.V.
31.14. Daiichi Sankyo Co. Ltd.
31.15. Boehringer Ingelheim International GmbH

32. Global Pulmonary Embolism Market Competitive Benchmarking

33. Global Pulmonary Embolism Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pulmonary Embolism Market

35. Pulmonary Embolism Market Future Outlook and Potential Analysis

35.1 Pulmonary Embolism Market In 2028 - Countries Offering Most New Opportunities
35.2 Pulmonary Embolism Market In 2028 - Segments Offering Most New Opportunities
35.3 Pulmonary Embolism Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ